Nuclear Membrane Disruption Precedes Cytoplasmic Tau in Anti-IgLON5 Disease

Anti-IgLON5 disease represents a unique clinical intersection where an autoimmune response triggers a progressive, neurodegenerative tauopathy [1, 2]. Patients typically present with a complex constellation of sleep disorders, bulbar dysfunction, and gait instability that can mimic primary neurodegenerative conditions like progressive supranuclear palsy [3, 4]. While the presence of IgLON5 antibodies is the diagnostic hallmark, the resulting brainstem-dominant tau pathology has long been considered a secondary, time-dependent phenomenon [5, 6]. The precise mechanism by which surface antibodies initiate intracellular protein aggregation remains a critical unknown in clinical neurology [7]. A recent study clarifies this timeline, offering fresh insights into the earliest cellular events that precede established neurodegeneration and highlighting a potential therapeutic window before irreversible damage occurs.